ABSTRACT
Spliceosomal RNAs are a family of small nuclear RNAs (snRNAs) that are essential for pre-mRNA splicing. All vertebrate spliceosomal snRNAs are extensively pseudouridylated after transcription. Pseudouridines in spliceosomal snRNAs are generally clustered in regions that are functionally important during splicing. Many of these modified nucleotides are conserved across species lines. Recent studies have demonstrated that spliceosomal snRNA pseudouridylation is catalyzed by two different mechanisms: an RNA-dependent mechanism and an RNA-independent mechanism. The functions of the pseudouridines in spliceosomal snRNAs (U2 snRNA in particular) have also been extensively studied. Experimental data indicate that virtually all pseudouridines in U2 snRNA are functionally important. Besides the currently known pseudouridines (constitutive modifications), recent work has also indicated that pseudouridylation can be induced at novel positions under stress conditions, thus strongly suggesting that pseudouridylation is also a regulatory modification.
Subject(s)
Animals , Base Sequence , Molecular Sequence Data , Nucleic Acid Conformation , Nucleotides , Metabolism , Oocytes , Cell Biology , Metabolism , Pseudouridine , Metabolism , RNA Precursors , Metabolism , RNA Splice Sites , RNA Splicing , RNA, Messenger , Genetics , Metabolism , RNA, Small Nuclear , Genetics , Metabolism , Ribonucleoproteins, Small Nuclear , Genetics , Metabolism , Saccharomyces cerevisiae , Genetics , Metabolism , Saccharomyces cerevisiae Proteins , Genetics , Metabolism , Spliceosomes , Genetics , Metabolism , Uridine , Metabolism , Xenopus , Genetics , MetabolismABSTRACT
Diffuse large B-cell lymphoma (DLBCL) represents the most common type of malignant lymphoma. DLBCL is heterogeneous with respect to morphology, immunophenotype, biology, clinical presentation and outcome. Constitutive activity of the NF-κB pathway may contribute to the poor prognosis of patients with activated B cell-like (ABC) subgroup of DLBCL, caspase recruitment domain 11 (CARD11) is the important signal protein in the signaling pathway of NF-κB. Furthermore, various pre-clinical data have proved the importance of CARD11 in DLBCL. This review summarizes the biological characteristics of CARD11, and its relationship with NF-κB signaling transduction pathway and the outcome of DLBCL, so that we can better understanding the pathogenesis and new therapeutic target of DLBCL.